VB

Vincent Brichard

Senior Vice-president at GlaxoSmithKline Biologicals

Brussels Metropolitan Area

Investor

Invests in

Locations:

Brussels

  • Min Investment:

    $1,000,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Skills

Clinical Trials
Oncology
Biotechnology
Infectious Diseases
Vaccines
Immunology
Medicine
Clinical Development
Life Sciences
Market Access
Drug Development
Diabetes
Biopharmaceuticals
Drug Discovery

Education

Lists including Vincent

AT
AS
AT
AH

All Series A Investors

14752 people

AM
AT
AS
AR

All Seed Investors

19695 people

Investments

Minervax

Series Unknown

Total Funding: $140M

ImCheck Therapeutics

Series B

Total Funding: $180M

Egle Therapeutics

Series A

Total Funding: $47M

FoRx Therapeutics

Seed

Total Funding: $11M

Work Experience

GB
GlaxoSmithKline Biologicals

2002

  • Senior Vice-President

    2002

    Head of Immunotherapeutics Business Units (including antigen-sepcific cancer immunotherapy and other Therapeutic vaccines, e.g. against Alzheimer's, diabetes, multiple sclerosis or smoking cessation

Louvain University Medical Oncology Unit

2000 - 2002

  • Oncologist/Tumor immunology

    2000 - 2002

    oncologist

Institut Curie

1998 - 2000

  • Medical Oncology Department

    1998 - 2000

    Medical Oncology/Tumor immunology